Images
The journal Biocentury Innovations has published an article on the study led by IRB Barcelona researchers Salvador Aznar Benitah and Fran Supek and first-authored by postdoctoral researcher Alexandra Avgustinova. The study has shown that increasing chromatin accessibility in cancer promotes tumour aggressiveness and does not reduce tumour mutation burden, as previously believed. The article refers to one of the main conclusions of the study, namely the need to evaluate the long-term effects of chromatin modifiers in tumour models before taking them into the clinic.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
